Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.

ABSTRACT:

Objective

To report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guérin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible.

Methods

We detail consecutive participants screened for the BRAVO randomised controlled trial comparing RC with BCG (International Standard Randomised Controlled Trial Number [ISRCTN]12509361). Patients were prospectively registered and case-note review used for outcomes. The primary outcome was overall survival. Secondary outcomes included recurrence, progression, metastasis, and bladder cancer-specific survival.

Results and limitations

A total of 193 patients were screened, including 106 (54.9%) who received BCG, 43 (22.3%) primary RC, 37 (1

SUBMITTER: Conroy S 

PROVIDER: S-EPMC11745995 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature